Saturday, December 31, 2022 9:20:58 PM
All roads lead to $RVVTF #Bucillamime and #viruses including #Covid19 and chronic auto-immune system issues...that we know Bucillamine can help with
https://www.theguardian.com/society/2018/dec/17/chronic-fatigue-syndrome-could-be-triggered-by-overactive-immune-system
"Sharpe acknowledged the study did not shed light on how to treat established cases of CFS. “it may give us some clue down the line,” he said. “If the thing is triggered by an abnormal or excessive immune response, if we could find a way to reduce that immune response, we might stop incident cases.”
Dr Charles Shepherd, medical advisor at the ME Association, welcomed the study. “It adds to the growing weight of scientific evidence which indicates that the body’s immune system is playing an important role in the causation of CFS.”
https://www.theguardian.com/society/2018/dec/17/chronic-fatigue-syndrome-could-be-triggered-by-overactive-immune-system
"Sharpe acknowledged the study did not shed light on how to treat established cases of CFS. “it may give us some clue down the line,” he said. “If the thing is triggered by an abnormal or excessive immune response, if we could find a way to reduce that immune response, we might stop incident cases.”
Dr Charles Shepherd, medical advisor at the ME Association, welcomed the study. “It adds to the growing weight of scientific evidence which indicates that the body’s immune system is playing an important role in the causation of CFS.”
Bullish
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
